In the business year of 2020/2021, we spent approximately EUR 45 million on research and development
Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing. More

Egis Has Been Awarded for being a ’Future Proof Organization’

Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.


New Unit Inaugurated at Egis’s Körmend Plant

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.


Environment Protection - Electric Cars in the Egis Fleet

It is important for us to protect the future of our planet, therefore we try to reduce our ecological footprint. Egis uses more and more electric cars in its fleet in order to minimize the harmful substance output.


Active Agent Production Renewed

By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox